These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

111 related items for PubMed ID: 1584743

  • 1. Effects of reactive oxygen intermediate scavengers on the antitoxoplasmic activity of activated macrophages.
    Saito A, Igarashi I, Miyahara K, Venturini C, Claveria FG, Hirose T, Suzuki N, Ono K.
    Parasitol Res; 1992; 78(1):28-31. PubMed ID: 1584743
    [Abstract] [Full Text] [Related]

  • 2. Correlation between release of reactive oxygen intermediates and inhibition of Toxoplasma multiplication in mouse peritoneal and alveolar macrophages and kidney cells after in vitro incubation with Obioactin, lonomycin A, muramyl dipeptide, lipopolysaccharide or Toxoplasma lysate antigen.
    Saito A, Sakurai H, Saito T, Taji S, Miyagami T, Suzuki N, Seitz HM, Osaki H.
    Zentralbl Bakteriol Mikrobiol Hyg A; 1987 May; 264(3-4):446-54. PubMed ID: 3660981
    [Abstract] [Full Text] [Related]

  • 3. Toxoplasmacidal activity of Obioactin derived from hydrolyzed Toxoplasma immune bovine serum in heterologous cell cultures.
    Suzuki N, Izumo A, Sakurai H, Saito A, Miura H, Osaki H.
    Zentralbl Bakteriol Mikrobiol Hyg A; 1984 Mar; 256(3):356-66. PubMed ID: 6328796
    [Abstract] [Full Text] [Related]

  • 4. An in vitro study on the toxoplasmacidal activity of lonomycin A in host cells.
    Miyagami T, Takei Y, Matsumoto Y, Otake N, Mizoue K, Mizutani T, Omura S, Ozeki M, Suzuki N.
    J Antibiot (Tokyo); 1981 Feb; 34(2):218-23. PubMed ID: 7298512
    [Abstract] [Full Text] [Related]

  • 5. Macrophage activation through phagocytosis of muramyl dipeptide encapsulated in gelatin microspheres.
    Tabata Y, Ikada Y.
    J Pharm Pharmacol; 1987 Sep; 39(9):698-704. PubMed ID: 2890735
    [Abstract] [Full Text] [Related]

  • 6. Macrophage oxygen-dependent antimicrobial activity. I. Susceptibility of Toxoplasma gondii to oxygen intermediates.
    Murray HW, Cohn ZA.
    J Exp Med; 1979 Oct 01; 150(4):938-49. PubMed ID: 92521
    [Abstract] [Full Text] [Related]

  • 7. Effects of muramyl dipeptide on superoxide anion release and on anti-microbial activity of human macrophages.
    Wilson CB, Bohnsack J, Weaver WM.
    Clin Exp Immunol; 1982 Aug 01; 49(2):371-6. PubMed ID: 6290115
    [Abstract] [Full Text] [Related]

  • 8. Macrophage oxygen-dependent antimicrobial activity. II. The role of oxygen intermediates.
    Murray HW, Juangbhanich CW, Nathan CF, Cohn ZA.
    J Exp Med; 1979 Oct 01; 150(4):950-64. PubMed ID: 512587
    [Abstract] [Full Text] [Related]

  • 9. Macrophage activation for antitumour function by muramyl dipeptide-protein conjugates.
    Tabata Y, Ikada Y.
    J Pharm Pharmacol; 1990 Jan 01; 42(1):13-9. PubMed ID: 1969943
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Activated microglia inhibit multiplication of Toxoplasma gondii via a nitric oxide mechanism.
    Chao CC, Anderson WR, Hu S, Gekker G, Martella A, Peterson PK.
    Clin Immunol Immunopathol; 1993 May 01; 67(2):178-83. PubMed ID: 8519093
    [Abstract] [Full Text] [Related]

  • 12. Comparative effect of muramyl dipeptide in vivo and in vitro on the tumoricidal activity of rat peritoneal macrophages.
    Reisser D, Jeannin JF, Lagadec P, Martin F.
    J Biol Response Mod; 1985 Oct 01; 4(5):460-3. PubMed ID: 4078593
    [Abstract] [Full Text] [Related]

  • 13. MDP(Lysyl)GDP, a nontoxic muramyl dipeptide derivative, inhibits cytokine production by activated macrophages and protects mice from phorbol ester- and oxazolone-induced inflammation.
    Zunic M, Bahr GM, Mudde GC, Meingassner JG, Lam C.
    J Invest Dermatol; 1998 Jul 01; 111(1):77-82. PubMed ID: 9665390
    [Abstract] [Full Text] [Related]

  • 14. [Antitumoral activation of rat peritoneal macrophages by muramyl dipeptide in vitro].
    Reisser D, Jeannin JF, Martin F.
    C R Seances Acad Sci III; 1982 Nov 08; 295(8):485-8. PubMed ID: 6819063
    [Abstract] [Full Text] [Related]

  • 15. Activation of rat alveolar macrophages by gamma interferon to inhibit Toxoplasma gondii in vitro.
    Badger AM, Hutchman JS, Sung CP, Bugelski PJ.
    J Leukoc Biol; 1987 Nov 08; 42(5):447-54. PubMed ID: 2824644
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Effect of obiopeptide and obioactin on the toxoplasmacidal activity, glucose consumption and ruffle formation in mouse macrophages.
    Fujii Y, Maki Y, Claveria FG, Igarashi I, Saito A, Ono K, Suzuki N.
    J Vet Med Sci; 1992 Apr 08; 54(2):351-3. PubMed ID: 1318754
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Marked enhancement of macrophage activation induced by synthetic muramyl dipeptide (MDP) conjugate using monoclonal anti-MDP antibodies.
    Leclerc C, Bahr GM, Chedid L.
    Cell Immunol; 1984 Jul 08; 86(2):269-77. PubMed ID: 6733783
    [Abstract] [Full Text] [Related]

  • 20. Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice.
    Krahenbuhl JL, Sharma SD, Ferraresi RW, Remington JS.
    Infect Immun; 1981 Feb 08; 31(2):716-22. PubMed ID: 7216470
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.